{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:18:06Z","timestamp":1784297886838,"version":"3.55.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s11845-024-03611-x","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T06:02:36Z","timestamp":1706767356000},"page":"1215-1222","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The second-line treatment of hepatocellular carcinoma with CalliSpheres drug-eluting bead transarterial chemoembolization combined with regorafenib: A safety and efficacy analysis"],"prefix":"10.1007","volume":"193","author":[{"given":"Song","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingdong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangsheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangji","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"issue":"1","key":"3611_CR1","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"PR Galle","year":"2018","unstructured":"Galle PR, Forner A, Llovet JM et al (2018) European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 69(1):182\u2013236","journal-title":"J Hepatol"},{"issue":"4","key":"3611_CR2","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V et al (2008) SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378\u2013390","journal-title":"N Engl J Med"},{"issue":"10126","key":"3611_CR3","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised Phase 3 non-inferiority trial. Lancet 391(10126):1163\u20131173","journal-title":"Lancet"},{"issue":"10064","key":"3611_CR4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","volume":"389","author":"J Bruix","year":"2017","unstructured":"Bruix J, Qin S, Merle P et al (2017) RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389(10064):56\u201366","journal-title":"Lancet"},{"issue":"1","key":"3611_CR5","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1717002","volume":"379","author":"GK Abou-Alfa","year":"2018","unstructured":"Abou-Alfa GK, Meyer T, Cheng AL et al (2018) Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 379(1):54\u201363","journal-title":"N Engl J Med"},{"issue":"2","key":"3611_CR6","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","volume":"20","author":"AX Zhu","year":"2019","unstructured":"Zhu AX, Kang YK, Yen CJ et al (2019) REACH-2 study investigators. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20(2):282\u2013296","journal-title":"Lancet Oncol"},{"issue":"1","key":"3611_CR7","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1080\/10717544.2021.1943057","volume":"28","author":"G Zhao","year":"2021","unstructured":"Zhao G, Liu S, Chen S et al (2021) Assessment of efficacy and safety by CalliSpheres versus HepaSpheres for drug-eluting bead transarterial chemoembolization in unresectable large hepatocellular carcinoma patients. Drug Deliv 28(1):1356\u20131362","journal-title":"Drug Deliv"},{"issue":"1","key":"3611_CR8","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/ijc.25864","volume":"129","author":"SM Wilhelm","year":"2011","unstructured":"Wilhelm SM, Dumas J, Adnane L et al (2011) Regorafenib (BAY 73\u20134506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129(1):245\u2013255","journal-title":"Int J Cancer"},{"issue":"7","key":"3611_CR9","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1158\/1535-7163.MCT-12-1162","volume":"12","author":"L Abou-Elkacem","year":"2013","unstructured":"Abou-Elkacem L, Arns S, Brix G et al (2013) Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model. Mol Cancer Ther 12(7):1322\u20131231","journal-title":"Mol Cancer Ther"},{"issue":"30","key":"3611_CR10","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.1200\/JCO.2011.37.1021","volume":"29","author":"TM Pawlik","year":"2011","unstructured":"Pawlik TM, Reyes DK, Cosgrove D et al (2011) Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol 29(30):3960\u20133967","journal-title":"J Clin Oncol"},{"issue":"10","key":"3611_CR11","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1111\/j.1349-7006.2008.00909.x","volume":"99","author":"JH Shim","year":"2008","unstructured":"Shim JH, Park JW, Kim JH et al (2008) Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci 99(10):2037\u20132044","journal-title":"Cancer Sci"},{"issue":"10","key":"3611_CR12","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1007\/s00432-021-03708-1","volume":"147","author":"F Cao","year":"2021","unstructured":"Cao F, Zheng J, Luo J et al (2021) Treatment efficacy and safety of regorafenib plus drug-eluting beads-transarterial chemoembolization versus regorafenib monotherapy in colorectal cancer liver metastasis patients who fail standard treatment regimens. J Cancer Res Clin Oncol 147(10):2993\u20133002","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"3611_CR13","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1186\/s12876-021-01967-3","volume":"21","author":"Y Han","year":"2021","unstructured":"Han Y, Cao G, Sun B et al (2021) Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study. BMC Gastroenterol 21(1):393","journal-title":"BMC Gastroenterol"},{"issue":"6","key":"3611_CR14","first-page":"616","volume":"31","author":"YC Gong","year":"2022","unstructured":"Gong YC, Shao GL (2022) Physicochemical properties of drug-eluting beads and their application to interventional therapy of liver cancer. Journal of Interventional Radiology 31(6):616\u2013622","journal-title":"Journal of Interventional Radiology"},{"issue":"12","key":"3611_CR15","first-page":"13931","volume":"13","author":"S Liu","year":"2021","unstructured":"Liu S, Yu G, Wang Q et al (2021) CalliSpheres\u00ae microspheres drug-eluting bead transhepatic artery chemoembolization with or without sorafenib for the treatment of large liver cancer: a multi-center retrospective study. Am J Transl Res 13(12):13931\u201313940","journal-title":"Am J Transl Res"},{"issue":"4","key":"3611_CR16","first-page":"1897","volume":"25","author":"M Bekir Hacioglu","year":"2020","unstructured":"Bekir Hacioglu M, Kostek O, Karabulut S et al (2020) Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: a real life data of multicenter study from Turkey. J BUON 25(4):1897\u20131903","journal-title":"J BUON"},{"issue":"3","key":"3611_CR17","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s10637-018-0707-5","volume":"37","author":"C Yoo","year":"2019","unstructured":"Yoo C, Park JW, Kim YJ et al (2019) Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma. Invest New Drugs 37(3):567\u2013572","journal-title":"Invest New Drugs"},{"issue":"12","key":"3611_CR18","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1634\/theoncologist.2015-0196","volume":"20","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Fan W, Wang Y et al (2015) Sorafenib with and without transarterial chemoembolization for advanced hepatocellular carcinoma with main portal vein tumor thrombosis: a retrospective analysis. Oncologist 20(12):1417\u20131424","journal-title":"Oncologist"},{"issue":"29","key":"3611_CR19","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000021191","volume":"99","author":"S Komiyama","year":"2020","unstructured":"Komiyama S, Numata K, Ogushi K et al (2020) Therapeutic effects of regorafenib after sorafenib monotherapy with advanced hepatocellular carcinoma including Child-Pugh classification B: a retrospective observational study. Medicine (Baltimore) 99(29):e21191","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"3611_CR20","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.jceh.2021.02.003","volume":"11","author":"A Mukund","year":"2021","unstructured":"Mukund A, Bhardwaj K, Choudhury A et al (2021) Survival and outcome in patients receiving drug-eluting beads transarterial chemoembolization for large hepatocellular carcinoma (>5 cm)[J]. J Clin Exp Hepatol 11(6):674\u2013681","journal-title":"J Clin Exp Hepatol"},{"issue":"4","key":"3611_CR21","doi-asserted-by":"publisher","first-page":"933","DOI":"10.2214\/AJR.20.24708","volume":"217","author":"L Zhang","year":"2021","unstructured":"Zhang L, Sun JH, Ji JS et al (2021) Imaging changes and clinical complications after drug-eluting bead versus conventional transarterial chemoembolization for unresectable hepatocellular carcinoma: multicenter study. AJR Am J Roentgenol 217(4):933\u2013943","journal-title":"AJR Am J Roentgenol"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-024-03611-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-024-03611-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-024-03611-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T02:33:16Z","timestamp":1716777196000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-024-03611-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["3611"],"URL":"https:\/\/doi.org\/10.1007\/s11845-024-03611-x","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]},"assertion":[{"value":"18 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was carried out with the approval by Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}